At the beginning of 2008, Crucell has signed a collaboration and commercialization agreement with Sanofi Pasteur, the vaccines division of Sanofi-Aventis Group, for Crucell’s rabies monoclonal antibodies to
The study is designed to confirm certain safety and efficacy results from Genta’s prior randomized trial of Genasense combined with dacarbazine (DTIC) in patients identified by a biomarker
The objective of this non-clinical study was to examine the effects of CK-1827452 in dogs with heart failure, either with or without pre-existing left ventricular hypertrophy (LVH). In
The move is part of the company’s overall strategy to continue improving product and component integration and increase operational efficiencies at all levels of the organization. The Philadelphia
According to New England Journal of Medicine, manufacturing revisions and forced label changes are also more common in drugs that get faster-than-normal approval by the FDA. The authors
The preclinical data show that virus selected for resistance to ANX-201 develop genetic mutations, some previously described for foscarnet-resistant virus, as well as unique genetic mutations not previously
Encorium will be utilizing its internal resources in Europe and North America to assist Protherics with program consulting, project management, site management and monitoring, data management, oversight of
The royalty payments included in the agreement are related to Nanogen’s patented MGB (minor groove binder) technology that has been licensed to Applied Biosystems (ABI) for use in
The patent was challenged jointly by generic companies Laboratorios Cinfa, Kern Pharma, Laboratorios Alter and Laboratorios Belmac and is one of four separate challenges to the enantiomer patent
BioAlliance Pharma’s third commercial partnership is potentially worth $12 million to the Paris-based firm, including $1.5 million on signature and a further $1.5 million on first sale in
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.